Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML

Age and comorbidities are important factors to be considered in the selection of tyrosine kinase inhibitors (TKIs) for first‐line treatment in patients with chronic myeloid leukemia in chronic phase (CML‐CP). However, it is yet unclear whether TKI selection, particularly, imatinib versus second‐gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Ono, Takaaki, Takahashi, Naoto, Kizaki, Masahiro, Kawaguchi, Tatsuya, Suzuki, Ritsuro, Yamamoto, Kazuhito, Ohnishi, Kazunori, Naoe, Tomoki, Matsumura, Itaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986084/
https://www.ncbi.nlm.nih.gov/pubmed/36336963
http://dx.doi.org/10.1111/cas.15642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986084/
https://www.ncbi.nlm.nih.gov/pubmed/36336963
http://dx.doi.org/10.1111/cas.15642

Ejemplares similares